A PHASE I CLINICAL TRIAL OF EPO906 IN COMBINATION WITH OXALIPLATIN IN PATIENTS WITH ADVANCED SOLID TUMORS

被引：0
|
作者：
Keefe, S. M. [1 ]
Avadhani, A. N. [1 ]
Flaherty, K. T. [1 ]
Redlinger, M. [1 ]
O'Dwyer, P. J. [1 ]
机构：
[1] Univ Penn, Philadelphia, PA 19104 USA
来源：
ANNALS OF ONCOLOGY | 2009年 / 20卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：42 / 42
页数：1
相关论文
共 50 条
  • [21] Lefitolimod in Combination with Ipilimumab in Patients with Advanced Solid Tumors: A Phase I Trial
    Nardo, Mirella
    Gouda, Mohamed A.
    Reilley, Matthew J.
    Biter, Amadeo B.
    Lim, Joann
    Bean, Stacie A.
    Nguyen, Ly M.
    Bhosale, Priya R.
    Ager, Casey R.
    Couillault, Coline A.
    Piha-Paul, Sarina A.
    Fu, Siqing
    Tsimberidou, Apostolia M.
    Yap, Timothy A.
    Naing, Aung
    Rodon, Jordi
    Subbiah, Vivek
    Karp, Daniel D.
    Curran, Michael A.
    Hong, David S.
    JOURNAL OF IMMUNOTHERAPY AND PRECISION ONCOLOGY, 2025, 8 (02) : 89 - 98
  • [22] A phase I study of celecoxib (C) and patupilone (EPO906) in patients (pts) with metastatic colorectal cancer (mCRC).
    Iqbal, S.
    El-Khoueiry, A. B.
    Yang, D.
    Cole, S.
    Boswell, W.
    Shriki, J.
    Ning, Y.
    Agafitei, R. D.
    Menendez, X.
    Lenz, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Phase I study of capecitabine and oxaliplatin in combination with the proteasome inhibitor bortezomib in patients with advanced solid tumors
    Cohen, Steven J.
    Engstrom, Paul F.
    Lewis, Nancy L.
    Langer, Corey J.
    McLaughlin, Susan
    Beard, Mary
    Weiner, Louis M.
    Meropol, Neal J.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2008, 31 (01): : 1 - 5
  • [24] Phase I and pharmacokinetic study of the multitargeted antifolate pemetrexed in combination with oxaliplatin in patients with advanced solid tumors
    Misset, JL
    Gamelin, E
    Campone, M
    Delaloge, S
    Latz, JE
    Bozec, L
    Fumoleau, P
    ANNALS OF ONCOLOGY, 2004, 15 (07) : 1123 - 1129
  • [25] Phase I Clinical Trial of Ipilimumab in Pediatric Patients with Advanced Solid Tumors
    Merchant, Melinda S.
    Wright, Matthew
    Baird, Kristin
    Wexler, Leonard H.
    Rodriguez-Galindo, Carlos
    Bernstein, Donna
    Delbrook, Cindy
    Lodish, Maya
    Bishop, Rachel
    Wolchok, Jedd D.
    Streicher, Howard
    Mackall, Crystal L.
    CLINICAL CANCER RESEARCH, 2016, 22 (06) : 1364 - 1370
  • [26] A phase I trial of the combination of erlotinib and tipifarnib in patients with advanced solid tumors.
    Ma, CX
    Croghan, G
    Reid, J
    Hanson, L
    Mandrekar, S
    Marks, R
    Adjei, A
    Furth, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 192S - 192S
  • [27] Phase I targeted combination trial of sorafenib and erlotinib in patients with advanced solid tumors
    Duran, Ignacio
    Hotte, Sebastien J.
    Hirte, Holger
    Chen, Eric X.
    MacLean, Martha
    Turner, Sandra
    Duan, Lixia
    Pond, Gregory R.
    Lathia, Chetan
    Walsh, Scott
    Wright, John J.
    Dancey, Janet
    Siu, Lillian L.
    CLINICAL CANCER RESEARCH, 2007, 13 (16) : 4849 - 4857
  • [28] Phase I clinical trial of oxaliplatin in children and adolescents with refractory solid tumors
    Spunt, Sheri L.
    Freeman, Burgess B., III
    Billups, Catherine A.
    McPherson, Valerie
    Khan, Raja B.
    Pratt, Charles B.
    Stewart, Clinton E.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (16) : 2274 - 2280
  • [29] An ongoing phase I trial of Tomudex® (T) in combination with oxaliplatin (L-OHP) in advanced solid tumors:: A promising and active combination
    Fizazi, K
    Baudin, E
    Ruffie, P
    Ducreux, M
    Soria, JC
    Le Chevalier, T
    Bonnay, M
    Couturas, O
    Fandi, A
    Armand, JP
    ANNALS OF ONCOLOGY, 1998, 9 : 120 - 120
  • [30] Results of a phase I trial of BAY 43-9006 in combination with oxaliplatin in patients with refractory solid tumors
    Kupsch, P
    Passarge, K
    Richly, H
    Wiesemann, K
    Hilger, RA
    Haase, CG
    Schwartz, B
    Scheulen, ME
    Seeber, S
    Strumberg, D
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 209S - 209S
12345